<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32203398</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>228</EndPage><MedlinePgn>213-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-020-0330-x</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) encompasses a spectrum of clinical syndromes characterized by progressive executive, behavioural and language dysfunction. The various FTD spectrum disorders are associated with brain accumulation of different proteins: tau, the transactive response DNA binding protein of 43 kDa (TDP43), or fused in sarcoma (FUS) protein, Ewing sarcoma protein and TATA-binding protein-associated factor 15 (TAF15) (collectively known as FET proteins). Approximately 60% of patients with FTD have autosomal dominant mutations in C9orf72, GRN or MAPT genes. Currently available treatments are symptomatic and provide limited benefit. However, the increased understanding of FTD pathogenesis is driving the development of potential disease-modifying therapies. Most of these drugs target pathological tau - this category includes tau phosphorylation inhibitors, tau aggregation inhibitors, active and passive anti-tau immunotherapies, and MAPT-targeted antisense oligonucleotides. Some of these therapeutic approaches are being tested in phase II clinical trials. Pharmacological approaches that target the effects of GRN and C9orf72 mutations are also in development. Key results of large clinical trials will be available in a few years. However, clinical trials in FTD pose several challenges, and the development of specific brain imaging and molecular biomarkers could facilitate the recruitment of clinically homogenous groups to improve the chances of positive clinical trial results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7220-0656</Identifier><AffiliationInfo><Affiliation>Unit of Epidemiological Research on Aging "GreatAGE Study", National Institute of Gastroenterology and Research Hospital IRCCS "S. De Bellis" Castellana Grotte, Bari, Italy. geriat.dot@uniba.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozupone</LastName><ForeName>Madia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Geriatric Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniele</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watling</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Chiesi Farmaceutici, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannelli</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Epidemiological Research on Aging "GreatAGE Study", National Institute of Gastroenterology and Research Hospital IRCCS "S. De Bellis" Castellana Grotte, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Imbimbo</LastName><ForeName>Bruno P</ForeName><Initials>BP</Initials><Identifier Source="ORCID">0000-0002-0327-7262</Identifier><AffiliationInfo><Affiliation>Department of Research and Development, Chiesi Farmaceutici, Parma, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034802">RNA-Binding Protein EWS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102041">TAF15 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035381">TATA-Binding Protein Associated Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050257">Tubulin Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018888" MajorTopicYN="N">Aphasia, Primary Progressive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="Y">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016233" MajorTopicYN="N">Immunotherapy, Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034802" MajorTopicYN="N">RNA-Binding Protein EWS</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035381" MajorTopicYN="N">TATA-Binding Protein Associated Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050257" MajorTopicYN="N">Tubulin Modulators</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32203398</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-0330-x</ArticleId><ArticleId IdType="pii">10.1038/s41582-020-0330-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bang, J., Spina, S. &amp; Miller, B. L. Frontotemporal dementia. Lancet 386, 1672&#x2013;1682 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00461-4</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId><ArticleId IdType="pmc">5970949</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist, I. T. et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86, 1736&#x2013;1743 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002638</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId><ArticleId IdType="pmc">4854589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, R. M. &amp; Boxer, A. L. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J. Neurochem. 138, 211&#x2013;221 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13640</ArticleId><ArticleId IdType="pubmed">27306957</ArticleId><ArticleId IdType="pmc">5217534</ArticleId></ArticleIdList></Reference><Reference><Citation>Young, J. J. et al. Frontotemporal dementia: latest evidence and clinical implications. Ther. Adv. Psychopharmacol. 8, 33&#x2013;48 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045125317739818</ArticleId><ArticleId IdType="pubmed">29344342</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. A critical appraisal of amyloid-&#x3b2;-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73&#x2013;88 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0116-6</ArticleId><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihl, R. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer&#x2019;s disease and other dementias. World J. Biol. Psychiatry 12, 2&#x2013;32 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/15622975.2010.538083</ArticleId><ArticleId IdType="pubmed">21288069</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey, E. D., Putnam, K. T. &amp; Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66, 17&#x2013;22 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000191304.55196.4d</ArticleId><ArticleId IdType="pubmed">16401839</ArticleId><ArticleId IdType="pmc">4499854</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst. Rev. 3, CD009444 (2015).</Citation></Reference><Reference><Citation>Buoli, M. et al. Pharmacological management of psychiatric symptoms in frontotemporal dementia: a systematic review. J. Geriatr. Psychiatry Neurol. 30, 162&#x2013;169 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988717700506</ArticleId><ArticleId IdType="pubmed">28351199</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien, J. T. et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacol. 31, 147&#x2013;166 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881116680924</ArticleId><ArticleId IdType="pubmed">28103749</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, R. et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 21, 931&#x2013;937 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002512-200421140-00003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz, A. et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord. 25, 178&#x2013;185 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000113034</ArticleId><ArticleId IdType="pubmed">18196898</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan, I. et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57, 467&#x2013;473 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.3.467</ArticleId><ArticleId IdType="pubmed">11502915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi, T., Matsunaga, S. &amp; Iwata, N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr. Dis. Treat. 11, 2883&#x2013;2885 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S94430</ArticleId><ArticleId IdType="pubmed">26648724</ArticleId><ArticleId IdType="pmc">4648602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercelletto, M. et al. Memantine in behavioral variant frontotemporal dementia: negative results. J. Alzheimer Dis. 23, 749&#x2013;759 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101632</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer, A. L. et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 12, 149&#x2013;156 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70320-4</ArticleId><ArticleId IdType="pubmed">23290598</ArticleId><ArticleId IdType="pmc">3756890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez, M. F. et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatr. 15, 84&#x2013;87 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JGP.0000231744.69631.33</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrini, G. et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol. Scand. 103, 123&#x2013;125 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2001.103002123.x</ArticleId><ArticleId IdType="pubmed">11227131</ArticleId></ArticleIdList></Reference><Reference><Citation>Liepelt, I. et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 6, 70&#x2013;74 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.04.1231</ArticleId><ArticleId IdType="pubmed">20129321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone, M. et al. Pharmacotherapy for the treatment of depression in patients with Alzheimer&#x2019;s disease: a treatment-resistant depressive disorder. Expert Opin. Pharmacother. 19, 823&#x2013;842 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2018.1471136</ArticleId><ArticleId IdType="pubmed">29726758</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartz, J. R. et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J. Clin. Psychiatry 58, 212&#x2013;216 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v58n0506</ArticleId><ArticleId IdType="pubmed">9184615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow, T. W. &amp; Mendez, M. F. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen. 17, 267&#x2013;272 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153331750201700504</ArticleId><ArticleId IdType="pubmed">12392261</ArticleId><ArticleId IdType="pmc">5841918</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, R. et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. Eur. Neurol. 49, 13&#x2013;19 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000067021</ArticleId><ArticleId IdType="pubmed">12464713</ArticleId></ArticleIdList></Reference><Reference><Citation>Deakin, J. B. et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 172, 400&#x2013;408 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-003-1686-5</ArticleId><ArticleId IdType="pubmed">14666399</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann, N. et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am. J. Geriatr. Psychiatry 20, 789&#x2013;797 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e31823033f3</ArticleId><ArticleId IdType="pubmed">21878805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, L. E. et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain 138, 1961&#x2013;1975 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv133</ArticleId><ArticleId IdType="pubmed">26001387</ArticleId><ArticleId IdType="pmc">5412666</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, S. et al. Citalopram improves obsessive-compulsive crossword puzzling in frontotemporal dementia. Case Rep. Neurol. 11, 94&#x2013;105 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000495561</ArticleId><ArticleId IdType="pubmed">31011326</ArticleId><ArticleId IdType="pmc">6465705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebert, F. et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord. 17, 355&#x2013;359 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000077171</ArticleId><ArticleId IdType="pubmed">15178953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez, M. F., Shapira, J. S. &amp; Miller, B. L. Stereotypical movements and frontotemporal dementia. Mov. Disord. 20, 742&#x2013;745 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20465</ArticleId><ArticleId IdType="pubmed">15786492</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodan, C. I., Monnon, M. &amp; Ross, E. D. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J. Neurol. Neurosurg. Psychiatry 80, 1416&#x2013;1417 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.173260</ArticleId><ArticleId IdType="pubmed">19917830</ArticleId></ArticleIdList></Reference><Reference><Citation>Anneser, J. M., Jox, R. J. &amp; Borasio, G. D. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph. Lateral Scler. 8, 189&#x2013;190 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960601073543</ArticleId><ArticleId IdType="pubmed">17538783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda, M. et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement. Geriatr. Cogn. Disord. 17, 117&#x2013;121 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000076343</ArticleId><ArticleId IdType="pubmed">14739531</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, I. M., Scott, K. &amp; Harborne, G. Serotonine and depression in frontal lobe dementia. Am. J. Psychiatry 152, 645 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7694920</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. Progresses in treating agitation: a major clinical challenge in Alzheimer&#x2019;s disease. Expert Opin. Pharmacother. 16, 2581&#x2013;2588 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2015.1092520</ArticleId><ArticleId IdType="pubmed">26389682</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg, Y. A. et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int. J. Geriatr. Psychiatr. 18, 67&#x2013;72 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.774</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, R. C. &amp; Resch, D. S. Case of Pick&#xb4;s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J. Clin. Psychopharmacol. 20, 384&#x2013;385 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004714-200006000-00018</ArticleId><ArticleId IdType="pubmed">10831030</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellgiebel, A. et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J. Biol. Psychiatry 8, 123&#x2013;126 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622970601016538</ArticleId><ArticleId IdType="pubmed">17455105</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, R. et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer&#x2019;s disease and other dementias: a 24-month follow-up of 68 patients. Am. J. Alzheimers Dis. Other Demen. 18, 205&#x2013;214 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153331750301800410</ArticleId><ArticleId IdType="pubmed">12955785</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha, M. K. et al. A case of frontotemporal dementia presenting with treatment-refractory psychosis and extreme violence: Response to combination of clozapine, medroxyprogesterone, and sertraline. J. Clin. Psychopharmacol. 35, 732&#x2013;733 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0000000000000414</ArticleId><ArticleId IdType="pubmed">26479224</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl, L. et al. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr. Dis. Treat. 10, 297&#x2013;310 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24600223</ArticleId><ArticleId IdType="pmc">3928059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges, J. R. et al. Clinicopathotogical correlates in frontotemporal dementia. Ann. Neurol. 56, 399&#x2013;406 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20203</ArticleId><ArticleId IdType="pubmed">15349867</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman, L. S. et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents, Council on Scientific Affairs, American Medical Association. JAMA 279, 1100&#x2013;1107 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.14.1100</ArticleId><ArticleId IdType="pubmed">9546570</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey, E. D. et al. Stimulant treatment of frontotemporal dementia in 8 patients. J. Clin. Psychiatry 69, 1981&#x2013;1982 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v69n1219a</ArticleId><ArticleId IdType="pubmed">19203481</ArticleId><ArticleId IdType="pmc">4489562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman, S. et al. Methylphenidate (&#x2018;Ritalin&#x2019;) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 31, 651&#x2013;658 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300886</ArticleId><ArticleId IdType="pubmed">16160709</ArticleId><ArticleId IdType="pmc">1852060</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, D. A. et al. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann. Neurol. 56, 750 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20301</ArticleId><ArticleId IdType="pubmed">15505780</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler, G., Teufel, M. &amp; Drach, L. M. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int. J. Geriatr. Psychiatry 18, 653&#x2013;655 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.894</ArticleId><ArticleId IdType="pubmed">12833310</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti, R. et al. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int. J. Geriatr. Psychiatry 17, 391&#x2013;392 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.602</ArticleId><ArticleId IdType="pubmed">11994896</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesso, S. et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain 134, 2493&#x2013;2501 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr171</ArticleId><ArticleId IdType="pubmed">21859765</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger, E. C. et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology 84, 174&#x2013;181 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001133</ArticleId><ArticleId IdType="pubmed">25503617</ArticleId><ArticleId IdType="pmc">4336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Callegari, I. et al. Agomelatine improves apathy in frontotemporal dementia. Neurodegener. Dis. 16, 352&#x2013;356 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445873</ArticleId><ArticleId IdType="pubmed">27229348</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi, V. et al. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: a systematic review. Neurosci. Biobehav. Rev. 95, 480&#x2013;498 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2018.10.022</ArticleId><ArticleId IdType="pubmed">30395922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardini, M. et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener. Dis. 15, 58&#x2013;62 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369811</ArticleId><ArticleId IdType="pubmed">25592742</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin, K. et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 17, 84&#x2013;93 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30408-8</ArticleId><ArticleId IdType="pubmed">29263011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard, H. B. Pharmacokinetics and dynamics of a ketogenic intervention in Alzheimer&#x2019;s disease and frontotemporal dementia. Alzheimers Dement. 13, p838 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.07.276</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456&#x2013;2477 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId><ArticleId IdType="pmc">3170532</ArticleId></ArticleIdList></Reference><Reference><Citation>Capozzo, R. et al. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimers Dement. 13, 858&#x2013;869 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.011</ArticleId><ArticleId IdType="pubmed">28264768</ArticleId><ArticleId IdType="pmc">6232845</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006&#x2013;1014 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId><ArticleId IdType="pmc">3059138</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853&#x2013;864 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId><ArticleId IdType="pmc">5516529</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496&#x2013;503 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId><ArticleId IdType="pmc">3590050</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong, M. J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 153&#x2013;174 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. Frontotemporal dementia and related disorders: deciphering the enigma. Ann. Neurol. 64, 4&#x2013;14 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21426</ArticleId><ArticleId IdType="pubmed">18668533</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137&#x2013;153 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId><ArticleId IdType="pmc">3232515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton, M. et al. Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922&#x2013;2931 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp214</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId><ArticleId IdType="pmc">2768659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski, T. J. Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205&#x2013;1208 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595&#x2013;2609 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr201</ArticleId><ArticleId IdType="pubmed">21856723</ArticleId><ArticleId IdType="pmc">3170539</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff, J. et al. Transportin1: a marker of FTLD-FUS. Acta Neuropathol. 122, 591&#x2013;600 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0863-6</ArticleId><ArticleId IdType="pubmed">21847626</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi, F. M. &amp; Miller, B. L. A clinicopathological approach to the diagnosis of dementia. Nat. Rev. Neurol. 13, 457&#x2013;476 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.96</ArticleId><ArticleId IdType="pubmed">28708131</ArticleId><ArticleId IdType="pmc">5771416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 134, 2565&#x2013;2581 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr198</ArticleId><ArticleId IdType="pubmed">21908872</ArticleId><ArticleId IdType="pmc">3170537</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini, M. G. &amp; Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry, D. C. et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 140, 3329&#x2013;3345 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx254</ArticleId><ArticleId IdType="pubmed">29053860</ArticleId><ArticleId IdType="pmc">5841140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailliot, C. et al. Phosphorylation of specific sets of tau isoforms explains different neurodegeneration processes. FEBS Lett. 433, 201&#x2013;204 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)00910-7</ArticleId><ArticleId IdType="pubmed">9744794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant, N., Wattez, A. &amp; Delacourte, A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively &#x201c;exon 10&#x201d; isoforms. J. Neurochem. 72, 1243&#x2013;1249 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0721243.x</ArticleId><ArticleId IdType="pubmed">10037497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant, N. et al. Different distribution of phosphorylated tau protein isoforms in Alzheimer&#x2019;s and Pick&#x2019;s diseases. FEBS Lett. 412, 578&#x2013;582 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(97)00859-4</ArticleId><ArticleId IdType="pubmed">9276470</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo, T. et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547&#x2013;556 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/61.6.547</ArticleId><ArticleId IdType="pubmed">12071638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio, E. H. et al. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J. Neuropathol. Exp. Neurol. 60, 328&#x2013;341 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.4.328</ArticleId><ArticleId IdType="pubmed">11305868</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M. &amp; Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240&#x2013;250 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.08.007</ArticleId><ArticleId IdType="pubmed">15615642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, Z. et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol. 122, 415&#x2013;428 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0857-4</ArticleId><ArticleId IdType="pubmed">21773886</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin, D. J. et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 129, 469&#x2013;491 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1380-1</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. &amp; Mackenzie, I. R. Review: neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol. Appl. Neurobiol. 45, 19&#x2013;40 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12526</ArticleId><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111&#x2013;113 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId><ArticleId IdType="pmc">3285143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. &amp; Neumann, M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 134, 79&#x2013;96 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone, C. et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 79, 995&#x2013;1001 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182684634</ArticleId><ArticleId IdType="pubmed">22875086</ArticleId><ArticleId IdType="pmc">3430710</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478&#x2013;484 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1199214</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme, P. et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 181, 37&#x2013;41 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200712039</ArticleId><ArticleId IdType="pubmed">18378771</ArticleId><ArticleId IdType="pmc">2287280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 66, 152&#x2013;157 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31803020b9</ArticleId><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId><ArticleId IdType="pmc">3202986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash, P. E. et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId><ArticleId IdType="pmc">3593233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron, T. F. et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829&#x2013;844 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId><ArticleId IdType="pmc">3830741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori, K. et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1189-3</ArticleId><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu, T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson, Y. S. et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 2, 70 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-70</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId><ArticleId IdType="pmc">4229740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 130, 845&#x2013;861 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1476-2</ArticleId><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 124, 705&#x2013;716 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1020-6</ArticleId><ArticleId IdType="pubmed">22842875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131, 1282&#x2013;1293 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn061</ArticleId><ArticleId IdType="pubmed">18362096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns, N. J. et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63, 1376&#x2013;1384 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000139809.16817.DD</ArticleId><ArticleId IdType="pubmed">15505152</ArticleId><ArticleId IdType="pmc">3516854</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz, D. G. et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617&#x2013;627 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0598-9</ArticleId><ArticleId IdType="pubmed">19830439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaka, H., Matsumoto, S. &amp; Imai, T. An adult-onset case of sporadic motor neuron disease with basophilic inclusions. Acta Neuropathol. 80, 660&#x2013;665 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00307636</ArticleId><ArticleId IdType="pubmed">1703386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami, I. et al. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma associated frontotemporal lobar degeneration. Acta Neuropathol. Commun. 4, 36 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0304-9</ArticleId><ArticleId IdType="pubmed">27044537</ArticleId><ArticleId IdType="pmc">4820861</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin, H. et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33&#x2013;41 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0698-6</ArticleId><ArticleId IdType="pubmed">20490813</ArticleId><ArticleId IdType="pmc">2887939</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski, G. et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806&#x2013;808 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1609</ArticleId><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee, J. et al. CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum. Mol. Genet. 17, 313&#x2013;322 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm309</ArticleId><ArticleId IdType="pubmed">17956895</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs, A. M. et al. Frontotemporal dementia caused by CHMP2B mutations. Curr. Alzheimer Res. 8, 246&#x2013;251 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795563764</ArticleId><ArticleId IdType="pubmed">21222599</ArticleId><ArticleId IdType="pmc">3182073</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman, D. S. et al. Dementia lacking distinctive histologic features: a common non- Alzheimer degenerative dementia. Neurology 40, 251&#x2013;256 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.40.2.251</ArticleId><ArticleId IdType="pubmed">2300243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1&#x2013;4 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0612-2</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman, J. S. et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65, 1817&#x2013;1819 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000187068.92184.63</ArticleId><ArticleId IdType="pubmed">16344531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451&#x2013;1456 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bf997a</ArticleId><ArticleId IdType="pubmed">19884572</ArticleId><ArticleId IdType="pmc">2779007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood, E. M. et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 70, 1411&#x2013;1417 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.3956</ArticleId><ArticleId IdType="pubmed">24081456</ArticleId><ArticleId IdType="pmc">3906581</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves, C. V. &amp; Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075&#x2013;2086 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId><ArticleId IdType="pmc">6647117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129, 3081&#x2013;3090 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl271</ArticleId><ArticleId IdType="pubmed">17071926</ArticleId></ArticleIdList></Reference><Reference><Citation>Masellis, M. et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 129, 3115&#x2013;3123 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl276</ArticleId><ArticleId IdType="pubmed">17030534</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno, F. et al. &#x201c;Frontotemporoparietal&#x201d; dementia: clinical phenotype associated with the c.709&#x2013;1G&gt;A PGRN mutation. Neurology 73, 1367&#x2013;1374 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bd82a7</ArticleId><ArticleId IdType="pubmed">19858458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti, B., Hutton, M. &amp; Wszolek, Z. Neurodegeneration: the molecular pathology of dementia and movement disorders (ed. Dickson, D.) 86&#x2013;102 (ISN Neuropath Press, 2003).</Citation></Reference><Reference><Citation>Pickering-Brown, S. M. et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 125, 732&#x2013;751 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf069</ArticleId><ArticleId IdType="pubmed">11912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377&#x2013;381 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1332</ArticleId><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Benajiba, L. et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 65, 470&#x2013;473 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21612</ArticleId><ArticleId IdType="pubmed">19350673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, J. et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75, 807&#x2013;814 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f07e0c</ArticleId><ArticleId IdType="pubmed">20668259</ArticleId><ArticleId IdType="pmc">2938970</ArticleId></ArticleIdList></Reference><Reference><Citation>Synofzik, M. et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol. Aging 33, 2949.e13-7 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.002</ArticleId><ArticleId IdType="pubmed">22892309</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber, I. et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70, 1403&#x2013;1410 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24042580</ArticleId><ArticleId IdType="pmc">4199096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth, S. et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329&#x2013;2345 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId><ArticleId IdType="pmc">4107737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier, C. et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77&#x2013;92 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId><ArticleId IdType="pmc">4470809</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, K. L. et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat. Commun. 15, 11253 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. TIA1 Mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron 95, 808&#x2013;816 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId><ArticleId IdType="pmc">5576574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante, S., Rouleau, G. A. &amp; Kabashi, E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 34, 812&#x2013;826 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo, M. et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging 71, 266.e1&#x2013;266.e10 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin, D. J. Tauopathies as clinicopathological entities. Parkinsonism Relat. Disord. 22, S29&#x2013;S33 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.09.020</ArticleId><ArticleId IdType="pubmed">26382841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl, P., Steinacker, P., Feneberg, E. &amp; Otto, M. Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. J. Neurochem. 138 (Suppl. 1), 184&#x2013;192 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13669</ArticleId><ArticleId IdType="pubmed">27186717</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. N., Lau, C. I. &amp; Lin, C. P. Precision Medicine for frontotemporal dementia. Front. Psychiatry 10, 75 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00075</ArticleId><ArticleId IdType="pubmed">30846947</ArticleId><ArticleId IdType="pmc">6393374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedl, T. J. et al. Proteomics approaches for biomarker and drug target discovery in ALS and FTD. Front. Neurosci. 13, 548 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00548</ArticleId><ArticleId IdType="pubmed">31244593</ArticleId><ArticleId IdType="pmc">6579929</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId><ArticleId IdType="pmc">5958625</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer, A. L. et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 9, 189&#x2013;198 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.03.003</ArticleId><ArticleId IdType="pubmed">23062850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, W. et al. Assessment of CSF Ab42 as an aid to discriminating Alzheimer&#x2019;s disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies. J. Neurol. Sci. 345, 26&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.07.015</ArticleId><ArticleId IdType="pubmed">25086857</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten, A. C. et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49, 353&#x2013;366 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21342021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, W. et al. Does CSF p-tau181 help to discriminate Alzheimer&#x2019;s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J. Neural. Transm. 121, 1541&#x2013;1553 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1226-y</ArticleId><ArticleId IdType="pubmed">24817210</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillb&#xe4;ck, T. et al. Cerebrospinal fluid tau and amyloid-&#x3b2;1-42 in patients with dementia. Brain 138, 2716&#x2013;2731 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv181</ArticleId><ArticleId IdType="pubmed">26133663</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldeiras, I. et al. Cerebrospinal fluid Ab40 is similarly reduced in patients with Frontotemporal lobar degeneration and Alzheimer&#x2019;s disease. J. Neurol. Sci. 358, 308&#x2013;316 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.09.022</ArticleId><ArticleId IdType="pubmed">26388316</ArticleId><ArticleId IdType="pmc">26388316</ArticleId></ArticleIdList></Reference><Reference><Citation>Struyfs, H. et al. Cerebrospinal fluid P-Tau<sub>181P</sub>: biomarker for improved differential dementia diagnosis. Front. Neurol. 6, 138 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00138</ArticleId><ArticleId IdType="pubmed">26136723</ArticleId><ArticleId IdType="pmc">26136723</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong, D. et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936&#x2013;938 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.107326</ArticleId><ArticleId IdType="pubmed">17314187</ArticleId><ArticleId IdType="pmc">2117885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerr, I. et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 14, 751&#x2013;763 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.12.008</ArticleId><ArticleId IdType="pubmed">29391125</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert, M. K. CSF neurofilament light chain but not FLT3 ligand discriminates Parkinsonian disorders. Front. Neurol. 6, 91 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00091</ArticleId><ArticleId IdType="pubmed">25999911</ArticleId><ArticleId IdType="pmc">4419719</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdalinou, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240&#x2013;1247 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309562</ArticleId><ArticleId IdType="pubmed">25589779</ArticleId><ArticleId IdType="pmc">4564944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, W. T. et al. Reduced CSF p-Tau<sub>181</sub> to Tau ratio is a biomarker for FTLD-TDP. Neurol. 81, 1945&#x2013;1952 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000436625.63650.27</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortvelyessy, P. et al. CSF biomarkers of neurodegeneration in progressive non-fluent aphasia and other forms of frontotemporal dementia: clues for pathomechanisms? Front. Neurol. 9, 504 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00504</ArticleId><ArticleId IdType="pubmed">30013506</ArticleId><ArticleId IdType="pmc">6036143</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter, L. H. H. et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231&#x2013;e1239 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005261</ArticleId><ArticleId IdType="pubmed">29514947</ArticleId><ArticleId IdType="pmc">5890612</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiani, M. S. et al. Plasma tau is increased in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 89, 804&#x2013;807 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317260</ArticleId><ArticleId IdType="pubmed">29440230</ArticleId><ArticleId IdType="pmc">6204947</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens, J. &amp; Van Broeckhoven, C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet. 22, R77&#x2013;R87 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt349</ArticleId><ArticleId IdType="pubmed">23900071</ArticleId><ArticleId IdType="pmc">3782069</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni, B. et al. Csf p-tau<sub>181</sub>/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 86&#x2013;91 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.971812</ArticleId><ArticleId IdType="pubmed">25352065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni, R. et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 14, 1235&#x2013;1239 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000325058.10218.fc</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch, N. et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583&#x2013;591 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn352</ArticleId><ArticleId IdType="pubmed">2664450</ArticleId><ArticleId IdType="pmc">2664450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun, M. et al. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin. 22, 101711 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101711</ArticleId><ArticleId IdType="pubmed">6369219</ArticleId><ArticleId IdType="pmc">6369219</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alton, S. &amp; Lewis, J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front. Aging Neurosci. 6, 204 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">4137452</ArticleId><ArticleId IdType="pmc">4137452</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conti, L., Borroni, B. &amp; Baralle, M. New routes in frontotemporal dementia drug discovery. Expert Opin. Drug Discov. 12, 659&#x2013;671 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2017.1329294</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Rev. Neurother. 19, 397&#x2013;408 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1606715</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel, D. N. et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141&#x2013;1154 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.3.10.1141</ArticleId><ArticleId IdType="pubmed">275678</ArticleId><ArticleId IdType="pmc">275678</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M. et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis, A., Brown, W. M. &amp; Kosik, K. S. Structure and novel exons of the human tau gene. Biochemistry 3, 10626&#x2013;10633 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00158a027</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky, V. N. What does it mean to be natively unfolded? Eur. J. Biochem. 269, 2&#x2013;12 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0014-2956.2001.02649.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan, S. et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47, 10526&#x2013;10539 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi800783d</ArticleId><ArticleId IdType="pubmed">18783251</ArticleId><ArticleId IdType="pmc">18783251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindwall, G. &amp; Cole, R. D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301&#x2013;5305 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6425287</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes, B. B. &amp; Diamond, M. I. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J. Biol. Chem. 18, 19855&#x2013;19861 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R114.549295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. &amp; Warren, J. D. Phenotypic signatures of genetic frontotemporal dementia. Curr. Opin. Neurol. 24, 542&#x2013;549 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32834cd442</ArticleId><ArticleId IdType="pubmed">21986680</ArticleId><ArticleId IdType="pmc">21986680</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazacharias, A. et al. Bipolar disorder and frontotemporal dementia: an intriguing association. J. Alzheimers Dis. 55, 973&#x2013;979 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160860</ArticleId><ArticleId IdType="pubmed">27802240</ArticleId><ArticleId IdType="pmc">27802240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, M. et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25326&#x2013;25332 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.40.25326</ArticleId><ArticleId IdType="pubmed">9312151</ArticleId><ArticleId IdType="pmc">9312151</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990&#x2013;6995 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500466102</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel, T. et al. Chronic lithium administration to FTDP-17 tau and GSK-3&#x3b2; overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445&#x2013;1555 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04139.x</ArticleId><ArticleId IdType="pubmed">17059563</ArticleId><ArticleId IdType="pmc">17059563</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00703677 (2015).</Citation></Reference><Reference><Citation>H&#xf6;glinger, G. U. et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov. Disord. 29, 479&#x2013;487 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa, E. et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470&#x2013;478 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik, C. M. et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 93, 11213&#x2013;11218 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.20.11213</ArticleId></ArticleIdList></Reference><Reference><Citation>Seripa, D. et al. Tau-directed approaches for the treatment of Alzheimer&#x2019;s disease: focus on leuco-methylthioninium. Expert Rev. Neurother. 16, 259&#x2013;277 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2016.1140039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer&#x2019;s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873&#x2013;2884 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31275-2</ArticleId><ArticleId IdType="pubmed">27863809</ArticleId><ArticleId IdType="pmc">5164296</ArticleId></ArticleIdList></Reference><Reference><Citation>TauRx Pharmaceuticals, Press Release at the 10th International Conference on Frontotemporal Dementias, Munich, August 31&#x2013;September 2 https://taurx.com/trx-237-007-phase-3-clinical-trial-update.pdf (2016).</Citation></Reference><Reference><Citation>Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154&#x2013;1162 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3951</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId><ArticleId IdType="pmc">4598295</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02422485 (2018).</Citation></Reference><Reference><Citation>Paholikova, K. et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J. Alzheimers Dis. 43, 915&#x2013;926 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140996</ArticleId><ArticleId IdType="pubmed">25147106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontsekova, E. et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer&#x2019;s disease model. Alzheimers Res. Ther. 6, 44 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt278</ArticleId><ArticleId IdType="pubmed">25478017</ArticleId><ArticleId IdType="pmc">4255368</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak, P. et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer&#x2019;s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123&#x2013;134 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30331-3</ArticleId><ArticleId IdType="pubmed">27955995</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. &amp; Logroscino, G. Anti-tau vaccine in Alzheimer&#x2019;s disease: a tentative step. Lancet Neurol. 16, 99&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30340-4</ArticleId><ArticleId IdType="pubmed">27955996</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak, P. et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 10, 108 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0436-1</ArticleId><ArticleId IdType="pubmed">30355322</ArticleId><ArticleId IdType="pmc">6201586</ArticleId></ArticleIdList></Reference><Reference><Citation>AXON Neuroscience SE. Axon Announces Positive Results From Phase II ADAMANT Trial for AADvac1 in Alzheimer&#x2019;s Disease. CISION PR Newswire https://www.prnewswire.com/news-releases/axon-announces-positive-results-from-phase-ii-adamant-trial-for-aadvac1-in-alzheimers-disease-300914509.html (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03174886 (2019).</Citation></Reference><Reference><Citation>Dai, C. L. et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J. Neural. Transm. 122, 607&#x2013;617 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1315-y</ArticleId><ArticleId IdType="pubmed">25233799</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. Tau-based therapeutics for Alzheimer&#x2019;s disease: active and passive immunotherapy. Immunotherapy 8, 1119&#x2013;1134 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2016-0019</ArticleId><ArticleId IdType="pubmed">27485083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright, J. et al. Human secreted tau increases amyloid-&#x3b2; production. Neurobiol. Aging 36, 693&#x2013;709 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.007</ArticleId><ArticleId IdType="pubmed">25442111</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02294851 (2017).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02460094 (2018).</Citation></Reference><Reference><Citation>Boxer, A. L. et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 18, 549&#x2013;558 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30139-5</ArticleId><ArticleId IdType="pubmed">31122495</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03068468 (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03658135 (2019).</Citation></Reference><Reference><Citation>Gosuranemab, Biogen&#x2019;s Anti-Tau Immunotherapy, Does not fly for PSP. ALZFORUM https://www.alzforum.org/news/research-news/gosuranemab-biogens-anti-tau-immunotherapy-does-not-fly-psp (2019).</Citation></Reference><Reference><Citation>Braak, H. &amp; Del Tredici, K. Alzheimer&#x2019;s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 121, 589&#x2013;595 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0825-z</ArticleId><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02494024 (2017).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03413319 (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02985879 (2020).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03391765 (2019).</Citation></Reference><Reference><Citation>Carroll, J. AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen. ENDPOINTS NEWS. https://endpts.com/abbvie-scraps-an-anti-tau-study-and-that-may-foretell-more-big-trouble-for-a-beleaguered-biogen/ (2019).</Citation></Reference><Reference><Citation>To Block Tau&#x2019;s Proteopathic Spread, Antibody Must Attack its Mid-Region. ALZFORUM. https://www.alzforum.org/news/conference-coverage/block-taus-proteopathic-spread-antibody-must-attack-its-mid-region (2018).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03464227 (2018).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04185415 (2020).</Citation></Reference><Reference><Citation>Jarskog, L. F. et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 38, 1245&#x2013;1252 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.23</ArticleId><ArticleId IdType="pubmed">23325325</ArticleId><ArticleId IdType="pmc">3656368</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt, D. C. et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 136, 25&#x2013;31 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2011.11.001</ArticleId><ArticleId IdType="pubmed">22169248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulih-Shultzman, I. et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323, 438&#x2013;449 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.129551</ArticleId><ArticleId IdType="pubmed">17720885</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka, Y. et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer&#x2019;s disease. J. Pharmacol. Exp. Ther. 325, 146&#x2013;153 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.130526</ArticleId><ArticleId IdType="pubmed">18199809</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouroukhin, Y. et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis. 56, 79&#x2013;94 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.04.012</ArticleId><ArticleId IdType="pubmed">23631872</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto, B. H. et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 35, 325&#x2013;326 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000348347</ArticleId><ArticleId IdType="pubmed">23594991</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer, A. L. et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 13, 676&#x2013;685 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70088-2</ArticleId><ArticleId IdType="pubmed">24873720</ArticleId><ArticleId IdType="pmc">4129545</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01056965 (2019).</Citation></Reference><Reference><Citation>Tsai, R. M. et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 77, 215&#x2013;224 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sud, R., Geller, E. T. &amp; Schellenberg, G. D. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids 3, e180 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2014.30</ArticleId><ArticleId IdType="pubmed">25072694</ArticleId><ArticleId IdType="pmc">4121519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalbfuss, B., Mabon, S. A. &amp; Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276, 42986&#x2013;42993 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105113200</ArticleId><ArticleId IdType="pubmed">11560926</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aag0481</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId><ArticleId IdType="pmc">5792300</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03186989 (2020).</Citation></Reference><Reference><Citation>Wang, Y. &amp; Mandelkow, E. Degradation of tau protein by autophagy and proteasomal pathways. Biochem. Soc. Trans. 40, 644&#x2013;652 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120071</ArticleId><ArticleId IdType="pubmed">22817709</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna, M. R. et al. Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimers Dement. 12, 1051&#x2013;1065 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.006</ArticleId><ArticleId IdType="pubmed">27751442</ArticleId><ArticleId IdType="pmc">5116305</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, W. et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl Acad. Sci. USA 104, 9511&#x2013;9516 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701055104</ArticleId><ArticleId IdType="pubmed">17517623</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagoz, G. E. et al. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156, 963&#x2013;974 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.01.037</ArticleId><ArticleId IdType="pubmed">24581495</ArticleId><ArticleId IdType="pmc">4263503</ArticleId></ArticleIdList></Reference><Reference><Citation>Soga, S., Akinaga, S. &amp; Shiotsu, Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr. Pharm. Des. 19, 366&#x2013;376 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161213804143617</ArticleId><ArticleId IdType="pubmed">22920907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey, C. A. et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 20, 753&#x2013;755 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-5343fje</ArticleId><ArticleId IdType="pubmed">16464956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal, A., Boehm, M. F. &amp; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283&#x2013;290 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2004.04.006</ArticleId><ArticleId IdType="pubmed">15177193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence, N. F., Sampat, R. M. &amp; Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552&#x2013;1555 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.292.5521.1552</ArticleId><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcelik, S. et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One 8, e62459 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062459</ArticleId><ArticleId IdType="pubmed">23667480</ArticleId><ArticleId IdType="pmc">3646815</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman, R., Cocca, R. &amp; Dong, Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One 10, e0142340 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142340</ArticleId><ArticleId IdType="pubmed">26540269</ArticleId><ArticleId IdType="pmc">4634963</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr, M. E., Sullivan, A. C. &amp; Frost, B. A brief overview of tauopathy: causes, consequences, and therapeutic strategies. Trends Pharmacol. Sci. 38, 637&#x2013;648 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.03.011</ArticleId><ArticleId IdType="pubmed">28455089</ArticleId><ArticleId IdType="pmc">5476494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F. et al. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA 101, 10804&#x2013;10809 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400348101</ArticleId><ArticleId IdType="pubmed">15249677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F. et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer&#x2019;s disease. Brain 132, 1820&#x2013;1832 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp099</ArticleId><ArticleId IdType="pubmed">19451179</ArticleId><ArticleId IdType="pmc">2702834</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghgraef, P. et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One 8, e84442 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084442</ArticleId><ArticleId IdType="pubmed">24376810</ArticleId><ArticleId IdType="pmc">3871570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastings, N. B. et al. Inhibition of O-GlcNAcase leads to elevation of OGlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol. Neurodegener. 12, 39 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0181-0</ArticleId><ArticleId IdType="pubmed">28521765</ArticleId><ArticleId IdType="pmc">5437664</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler, A. M. et al. Propagation of tau pathology in Alzheimer&#x2019;s disease: identification of novel therapeutic targets. Alzheimers Res. Ther. 5, 1&#x2013;8 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt214</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni, B. et al. Anti-AMPA GluA3 antibodies in frontotemporal dementia: a new molecular target. Sci. Rep. 7, 6723 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06117-y</ArticleId><ArticleId IdType="pubmed">28751743</ArticleId><ArticleId IdType="pmc">5532270</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici, A. et al. Autoimmunity and frontotemporal dementia. Curr. Alzheimer Res. 15, 602&#x2013;609 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205015666180119104825</ArticleId><ArticleId IdType="pubmed">29357796</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi, A. et al. Toward a glutamate hypothesis of frontotemporal dementia. Front. Neurosci. 13, 304 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00304</ArticleId><ArticleId IdType="pubmed">30983965</ArticleId><ArticleId IdType="pmc">6449454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, Y. et al. C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PLoS One 6, e21023 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021023</ArticleId><ArticleId IdType="pubmed">21698296</ArticleId><ArticleId IdType="pmc">3115958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer, B. C. et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 119, 409&#x2013;419 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId><ArticleId IdType="pmc">2880609</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita, M. et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 583, 2419&#x2013;2424 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.06.042</ArticleId><ArticleId IdType="pubmed">19560462</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd, J. D. et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screen. 19, 44&#x2013;56 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057113501553</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell, A. et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neurosci. 31, 1885&#x2013;1894 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5757-10.2011</ArticleId><ArticleId IdType="pubmed">21289198</ArticleId><ArticleId IdType="pmc">6623716</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici, A. et al. Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. Neurol. Sci. 35, 1215&#x2013;1219 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-014-1683-y</ArticleId><ArticleId IdType="pubmed">24569924</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik, B. et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 286, 16101&#x2013;16108 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.193433</ArticleId><ArticleId IdType="pubmed">21454553</ArticleId><ArticleId IdType="pmc">3091219</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzke, H. et al. Development of the novel histone deacetylase inhibitor EVP-0334 for CNS indications [Poster 831.21/I12]. 38th Annual Meeting for the Society of Neuroscience https://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=1981&amp;sKey=7608b1d6-24c8-4a0d-85e8-68357f77ef82&amp;cKey=b58f0420-5bde-407b-afe3-948d274e708b&amp;mKey=afea068d-d012-4520-8e42-10e4d1af7944 (2008).</Citation></Reference><Reference><Citation>Leventhal, L. et al. The histone deacetylase inhibitor EVP-0334 is pro-cognitive in mice [Poster 831.20/I11]. 38th Annual Meeting for the Society of Neuroscience https://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=1981&amp;sKey=7608b1d6-24c8-4a0d-85e8-68357f77ef82&amp;cKey=4256d6f9-3c58-4903-83ed-8d46d22972dd&amp;mKey=afea068d-d012-4520-8e42-10e4d1af7944 (2008).</Citation></Reference><Reference><Citation>Patzke, H. et al. The novel histone deacetylase inhibitor EVP-0334 is pro-cognitive in rats [Poster 886.4/FF106]. 39th Annual Meeting for the Society of Neuroscience https://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=74e6ee34-69bf-41db-a73b-fdf5d47df43e&amp;cKey=cfc48c84-c049-4c83-930b-2343b96acb62&amp;mKey=081f7976-e4cd-4f3d-a0af-e8387992a658 (2009).</Citation></Reference><Reference><Citation>De Muynck, L. &amp; Van Damme, P. In Frontiers in Clinical Drug Research &#x2013; Alzheimer Disorders (ed. Atta-ur-Rahman) 231&#x2013;291 (Bentham Books, 2015).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02149160 (2016).</Citation></Reference><Reference><Citation>Sha, S. J. et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement. 3, 507&#x2013;512 (2017).</Citation></Reference><Reference><Citation>Galimberti, D., Fenoglio, C. &amp; Scarpini, E. Progranulin as a therapeutic target for dementia. Expert Opin. Ther. Targets 22, 579&#x2013;585 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1487951</ArticleId><ArticleId IdType="pubmed">29889573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, F. et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68, 654&#x2013;667 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.034</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId><ArticleId IdType="pmc">2990962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, W. C. et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum. Mol. Genet. 23, 1467&#x2013;1478 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt534</ArticleId><ArticleId IdType="pubmed">24163244</ArticleId></ArticleIdList></Reference><Reference><Citation>Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients. BioSpace https://www.biospace.com/article/-alector-announces-data-from-on-going-phase-1b-trial-demonstrating-that-al001-reverses-progranulin-deficiency-in-frontotemporal-dementia-patients/ (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03987295 (2019).</Citation></Reference><Reference><Citation>Bright, F. et al. Neuroinflammation in frontotemporal dementia. Nat. Rev. Neurol. 15, 540&#x2013;555 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0231-z</ArticleId><ArticleId IdType="pubmed">31324897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478&#x2013;484 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1199214</ArticleId><ArticleId IdType="pubmed">21393509</ArticleId><ArticleId IdType="pmc">3104397</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler, C. J. et al. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Mol. Neurodegener. 11, 46 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0114-3</ArticleId><ArticleId IdType="pubmed">27341800</ArticleId><ArticleId IdType="pmc">4919863</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami, S. S. et al. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with &#x3b1;7 nicotinic acetylcholine receptor agonists. Biochem. Pharmacol. 97, 454&#x2013;462 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2015.07.016</ArticleId><ArticleId IdType="pubmed">26206194</ArticleId><ArticleId IdType="pmc">4859338</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation. BioSpace https://www.biospace.com/article/releases/prevail-therapeutics-announces-fda-orphan-drug-designation-granted-to-pr006-for-the-treatment-of-patients-with-frontotemporal-dementia-with-a-grn-mutation/ (2019).</Citation></Reference><Reference><Citation>Van Der Zee, J. et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 34, 363&#x2013;373 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, N. J. et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353, 708&#x2013;712 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf7791</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId><ArticleId IdType="pmc">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly, C. J. et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId><ArticleId IdType="pmc">4098943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen, D. et al. Targeting RNA foci in iPSC derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl Med. 5, 208ra149 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId><ArticleId IdType="pmc">4090945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 19, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, J. et al. Engineering duplex RNAs for challenging targets: recognition of GGGGCC/CCCCGG repeats at the ALS/FTD C9orf72 locus. Chem. Biol. 22, 1505&#x2013;1511 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2015.09.016</ArticleId><ArticleId IdType="pubmed">26584779</ArticleId><ArticleId IdType="pmc">4659491</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier, R. et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids 16, 26&#x2013;37 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId><ArticleId IdType="pmc">6393708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli, K. et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun. 7, 12143 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12143</ArticleId><ArticleId IdType="pubmed">27378374</ArticleId><ArticleId IdType="pmc">4935974</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii, S. et al. Treatment with a global methyltransferase inhibitor induces the intranuclear aggregation of ALS-linked FUS mutant in vitro. Neurochem. Res. 41, 826&#x2013;835 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-015-1758-z</ArticleId><ArticleId IdType="pubmed">26603295</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02372773 (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02365922 (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02590276 (2016).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02327845 (2019).</Citation></Reference><Reference><Citation>Desmarais, P. et al. Therapeutic trial design for frontotemporal dementia and related disorders. J. Neurol. Neurosurg. Psychiatry 90, 412&#x2013;442 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318603</ArticleId><ArticleId IdType="pubmed">30361298</ArticleId></ArticleIdList></Reference><Reference><Citation>Semler, E. et al. A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimers Res. Ther. 10, 41 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0345-3</ArticleId><ArticleId IdType="pubmed">5922300</ArticleId><ArticleId IdType="pmc">5922300</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni, A. M. et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain 142, 443&#x2013;459 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy319</ArticleId><ArticleId IdType="pubmed">6351779</ArticleId><ArticleId IdType="pmc">6351779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljubenkov, P. A. et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann. Clin. Transl Neurol. 5, 1250&#x2013;1263 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.643</ArticleId><ArticleId IdType="pubmed">6186942</ArticleId><ArticleId IdType="pmc">6186942</ArticleId></ArticleIdList></Reference><Reference><Citation>Modrego, P. &amp; Lobo, A. A good marker does not mean a good target for clinical trials in Alzheimer&#x2019;s disease: the amyloid hypothesis questioned. Neurodegener. Dis. Manag. 9, 119&#x2013;121 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2019-0006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>